Key Highlights

  • ResMed closed the divestiture of its MatrixCare software unit to Frazier Healthcare Partners on September 1, 2026.
  • For fiscal 2026, ResMed reported Revenue of about $5.65 billion, up roughly 10% year over year, with free Cash Flow of roughly $1.65 billion.
  • The company raised its quarterly Dividend 10% to $0.66 per share, reflecting strong cash generation.

ResMed has spent 2026 doing something few large-cap medical-technology companies manage consistently: growing Earnings at a double-digit clip while sharpening its portfolio. The San Diego-based sleep and respiratory-care leader closed the divestiture of its MatrixCare software unit on September 1, 2026, capping a fiscal year in which revenue crossed $5.6 billion. With the shares trading around $220 and a Market Value near $31-32 billion, the question for investors this September is whether ResMed (NYSE: RMD) can keep compounding as new competitive and clinical dynamics reshape the sleep market.

Company and Latest Development

ResMed designs and sells devices and cloud-connected software for sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions, alongside out-of-hospital software businesses. On July 7, 2026, the company announced a definitive agreement to sell MatrixCare, its senior-care electronic-health-record platform, to private-equity firm Frazier Healthcare Partners. The sale, framed as consistent with ResMed's "2030 strategy," closed on September 1, 2026, with Jonathan Lujan appointed chief executive of the standalone MatrixCare. The move lets ResMed concentrate Capital on its core sleep-and-respiratory Franchise and its Brightree software operations.

What Is Driving Attention Around RMD?

Two recent, verifiable events anchor the story: the August 6, 2026 fiscal fourth-quarter and full-year results, and the early-September completion of the MatrixCare divestiture. The stock's modest move on the reference session, down roughly half a percent, had no single clearly identifiable public catalyst and is best read as ordinary trading within a broader "top healthcare name" watch narrative rather than a reaction to fresh company news. The durable draw is ResMed's steady growth profile in a sector where consistency is scarce.

Key Numbers and Company Position

For fiscal 2026, which ended June 30, ResMed reported revenue of about $5.65 billion, up roughly 10% year over year. Fourth-quarter revenue rose about 9% to approximately $1.46 billion, with non-GAAP Diluted Earnings per Share of about $2.95, up 16%. Full-year non-GAAP diluted EPS came in near $11.17, up about 17%, and free cash flow reached roughly $1.65 billion. Reflecting that cash generation, ResMed raised its quarterly dividend 10% to $0.66 per share, an annualized rate near $2.64. The company remains one of the larger names in medical technology by market capitalization.

What Could Come Next?

With MatrixCare divested, attention shifts to how ResMed reinvests proceeds and sustains device and mask growth. The next scheduled catalyst is fiscal first-quarter 2027 results, typically reported in late October, which should show whether Demand momentum and gross-margin gains persist. Investors may also watch new-patient diagnosis trends, resupply revenue from connected devices, and any commentary on capital allocation, including Buybacks or bolt-on software deals.

Risks to Watch

A recurring debate concerns GLP-1 weight-loss medicines and their potential long-term effect on sleep-apnea prevalence and CPAP demand; ResMed has argued the drugs expand rather than shrink its market, but the thesis remains contested. Renewed competition, including rivals returning to the device market, could pressure share and pricing. Currency swings, reimbursement shifts and the premium valuation typical of high-quality MedTech add further sensitivity, meaning any growth wobble could weigh on sentiment.

Conclusion

ResMed enters September 2026 as a rare medtech grower that is also simplifying its structure, having closed the MatrixCare sale and posted double-digit full-year earnings growth with strong free cash flow and a raised dividend. The setup for RMD now rests on execution: sustaining core device and software momentum, deploying divestiture proceeds wisely, and navigating the GLP-1 debate. Investors may be watching the late-October fiscal first-quarter report and management's capital-allocation signals as the next key developments to monitor.